Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive
The Trump administration announced up to 200% tariffs on imported generic drugs, impacting India's pharmaceutical industry. However, generic drug imports will remain exempt from tariffs for the next two years, with a 100% tariff set to begin in August 2028. This exemption allows Indian manufacturers time to adapt and maintain competitiveness in the U.S. market.